IN THIS ISSUE - Drug Development & Delivery

8
New
Medicines
“Concert Pharmaceuticals, a clinical-stage
biopharmaceutical company, uses deuterium to
create and develop highly differentiated new
medicines. This is a significant departure from
the traditional use of deuterium modification
as an analytical probe for metabolic studies.
The company uses its DCE PlatformTM (Deuterium Chemical Entity) to develop new
drugs that are designed to have first-in-class
or best-in-class efficacy and/or safety.
Deuterium modification provides a novel
opportunity to develop new drugs by building
upon existing scientific or clinical experience,
potentially significantly reducing time, risk,
and expense.”
Drug Development & Delivery July/August 2012 Vol 12 No 6 Developing
p.67
51 Transdermal, Topical & Subcutaneous:
Non-Invasive Delivery to Expand
Product Line Extensions
Special Feature: Contributor Cindy H. Dubin asked delivery
system providers and contract developers and manufacturers to
describe their products and service offerings in their respective
areas of expertise and how they are changing the overall
landscape of the transdermal, topical, and subcutaneous markets.
59 Caisson Biotech: Innovation in Drug
Delivery Using a Naturally Occurring
Sugar Molecule
Drug Development Executive: Thomas Harlan, CEO of Caisson,
discusses how his company is improving the quality and delivery
of numerous medications, making life easier for patients, and
offering new ways for companies to enhance their drug pipeline.
67 Deuterium Modification as a New
Branch of Medicinal Chemistry to
Develop Novel, Highly Differentiated
Drugs
Philip Graham, PhD; Julie Liu, PhD; and David Turnquist, MBA;
show that deuterium modification may be used broadly to
improve upon previously known compounds or their analogs, in
turn offering potential benefits in a wide range of therapeutic
areas.
71 Accera, Inc: Discovering
Breakthroughs in Treating Central
Nervous System Disorders
Executive Summary: Holger Kunze, CEO of Accera, discusses the
company's novel approach to treating AD by addressing cerebral
hypometabolism.
DEPARTMENTS
Market News & Trends . . . . . . . . . . . . . . . . . . . . . 12
Regulatory Review . . . . . . . . . . . . . . . . . . . . . . . . 18
A Shrinking World: Realizing Regulatory Harmony
Excipient Update . . . . . . . . . . . . . . . . . . . . . . . . . 20
Directly Compressible “Medicated Chewing Gum
(MCG)” for Staying Alert
Technology & Services Showcase . . . . . . . . . . . . 62
External Delivery . . . . . . . . . . . . . . . . . . . . . . . . . 74
On Behalf of Private Equity